Articles tagged with Cancer Treatments
The April issue of SLAS Technology explores the therapeutic potential of reactive oxygen species (ROS) in applications ranging from wound healing and hair growth enhancement to cancer treatment and stem cell differentiation. However, limitations in controlling the temporal pattern of ROS release hinder their clinical translation.
The study analyzed 412 high-risk NMIBC patients treated with BCG therapy and found significant differences in outcomes according to specific features of the disease. Total median costs at one, two, and five years from start of BCG induction were $29,459, $55,267, and $117,361, respectively.
A recent review article published in Chinese Medical Journal explores the associations between psoriasis treatments and risks of cardiovascular diseases. The study finds that some treatments, such as TNF-α inhibitors and methotrexate, may reduce long-term cardiovascular risk, while others, like IL-12/23 inhibitors, may increase it.
Researchers created a novel platelet-based delivery system to target and penetrate tumors, combining photothermal therapy and immunotherapy. The biomimetic formulation demonstrated potent therapeutic effects against multiple types of cancer in murine models.
Researchers found that early intensive training improved motor and memory skills in a mouse model of Rett syndrome, delaying symptom onset. The study proposes newborn genetic testing followed by training to help girls retain milestones and improve quality of life.
Researchers at Kumamoto University found that aging cells in abdominal fluid contribute to peritoneal dissemination of gastric cancer by promoting cellular senescence and inflammation. This understanding could lead to new treatments targeting cancer cells and associated fibroblasts.
A phase III clinical trial showed that reducing steroid use in intermediate-fit older patients with newly diagnosed multiple myeloma yields similar outcomes to standard treatment. The adapted Rd treatment schedule spares steroid use after nine months, resulting in fewer adverse effects and improved event-free survival.
Scientists have discovered that large numbers of inherited genetic mutations collectively increase cancer risk, particularly for late-onset types. This breakthrough could lead to more effective early detection strategies and personalized cancer treatments tailored to an individual's genetics.
Research from Michigan State University highlights the racial disparity gap in cervical cancer information and follow-up, citing poor provider-patient communication as a key factor. The study suggests that improving education and using digital channels like text messages can help bridge this gap.
A minimally invasive treatment known as radiofrequency ablation (RFA) provides quick and sustained pain relief, improving quality of life for cancer patients with bone tumors. The benefits last more than 12 months, significantly outperforming radiation treatment.
Researchers at UIC have found that HPSE drives antiviral immunity, proliferative signals and cell death, with potential applications in treating dysregulation of the protein in various diseases. This discovery has broad implications for diseases such as cancer, atherosclerosis and autoimmune disorders.
A comprehensive analysis of biomarker testing reveals substantial variation in test utilization and treatment outcomes for stage IV NSCLC patients. Whole-genome sequencing may streamline diagnostic workflows and reduce complexity, but its cost-effectiveness remains uncertain.
A new study by Uppsala University found that unmarried patients and those with low educational attainment are less likely to be treated with a stem-cell transplantation for mantle cell lymphoma. The study suggests that this may result in poorer survival rates.
Researchers at Imperial College London have developed a new type of nanoprobe that uses second harmonic generation (SHG) to detect tumors more brightly and precisely than existing fluorescent nanoprobes. The biodegradable bioharmonophores attach specifically to tumor cells, reducing misrepresentation and improving detection sensitivity.
The CNIO team found that telomeres respond to external signals inducing cell proliferation and that blocking these signals can interfere with cancer cells becoming immortal. The study identifies telomeres as a key target of the AKT pathway, which plays a crucial role in tumorigenesis.
UC researchers found that cooperation between HER2 and MED1 genes promotes breast tumor growth, spread, and treatment resistance. Targeting MED1 alone or in combination with current therapies may be an effective treatment strategy for nearly 90% of breast cancer patients.
Researchers conducted a randomized intervention that improved continuity of care and interprofessional collaboration between lung cancer patients and their family physicians. The bidirectional exchange of patient information and care summaries led to enhanced patient and family physician perceptions of care, resulting in better outcomes.
Researchers have developed a novel stem-cell-based therapy targeting key targets in solid tumors, successfully prolonging the lifespan of mouse models with brain metastatic breast cancer. The engineered molecule EvDRL was delivered via allogeneic stem cells, which crossed the blood-brain barrier to home in on tumors.
A new study found that cancer patients who died by suicide were generally older and less likely to have histories of physical and psychiatric problems. These patients were also more likely to communicate about their suicidal intent before death.
A recent study published in Oncotarget identified elevated platelet counts as a prognostic factor for poor outcomes in patients with metastatic clear-cell renal cell carcinoma, particularly those classified as intermediate-risk. These findings highlight the importance of stratification models in guiding treatment decisions and design c...
Researchers will investigate how oral cancer releases mediators that sensitize and activate pain-sensing nerves, promoting cancer growth and pain. The goal is to develop novel approaches for treating oral cancer and pain.
Researchers at SCCL have found that CD4 T lymphocytes, which typically support immune responses, can also kill cancer cells directly. Up to a third of these cells were able to destroy tumor cells within five hours.
A study published in PLOS Pathogens reveals that bacterial toxin colibactin is produced in patients with urinary tract infections (UTIs), a potential link to bladder cancer. The researchers detected colibactin in 55 of 223 patient samples and found it to induce DNA damage in bladder cells.
A machine learning-based model predicts the probability of lung cancer among patients with multiple pulmonary nodules, achieving high accuracy in validation cohorts. The PKU-M model also surpasses prior logistic regression-based models and a previously established AI tool in diagnosis.
A large prospective study found a significant link between acid reflux disease and the development of cancers in the larynx and esophagus. The study, published in the American Cancer Society journal CANCER, estimated that approximately 17% of these cancers are associated with GERD.
A retrospective study by LSU Health New Orleans found that 63% of patients who dropped out of peritoneal dialysis did so due to psychosocial reasons. The researchers suggest that counseling and assisted dialysis programs may improve patient outcomes and quality of life.
A University of Oregon scientist has identified myeloid-derived suppressor cells and immunosuppressive cytokine IL-10 as early predictors of treatment response in trauma cases. Abnormal immune suppression may lead to poor bone healing, motivating the need for biomarkers that can predict patient outcomes.
Researchers are now able to use genomic alterations of tumors to determine prognosis and best treatment options for pediatric brain tumors. This approach has significantly changed the field of neurosurgery, enabling more effective treatment with fewer side effects.
A new algorithm developed by researchers at the University of Copenhagen can detect unusual disease trajectories in COPD patients that may indicate a different diagnosis, such as lung cancer. The algorithm was trained on data from 284,000 patients and identified approximately 69,000 typical disease trajectories.
A study published in Cell Death & Disease found that inhibiting the EZH2 protein can reduce cancer cell growth in multiple myeloma. The researchers discovered that certain metabolic pathways are altered in cells sensitive to EZH2 inhibition, providing potential markers for treatment response.
Researchers at Lund University discovered how E. coli bacteria target and degrade the MYC oncogene, a well-known contributor to many forms of cancer. This discovery has shown potent effects on tumor growth and increased survival in two different cancer models.
Trained medical scent dogs have been shown to effectively screen individuals for COVID-19 with high accuracy and speed. The dogs' keen sense of smell allows them to detect the virus's volatile organic compounds in tiny concentrations.
Scientists have discovered that the MYCN oncogene drives uncontrolled tumour growth in neuroblastoma patients. Inhibiting MYCN or its function may be a promising approach to treating the disease.
The Lundquist Institute will conduct a multi-site clinical trial to evaluate the efficacy and safety of psilocybin in individuals with severe psychological distress associated with terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.
A new Position Statement from UK stakeholders highlights the limited evidence supporting routine follow-up brain tumor imaging. Researchers propose future studies to assess cost effectiveness, quality of life, and treatment response to determine the value of interval imaging.
A new study found that elderly patients with locally advanced esophageal and esophagogastric junction cancer can achieve similar outcomes as younger patients when receiving recommended multimodal therapy. The therapy regimen includes initial chemoradiotherapy followed by surgical resection.
Researchers from INRS identify a protein called interleukin-21 that restores mitochondrial energy metabolism in immune cells, potentially leading to improved treatment options for HIV patients. The study also explores its applications in other diseases associated with persistent inflammation.
A study published in CANCER found an association between higher levels of nighttime artificial light and a 55% elevated risk of developing thyroid cancer. The association was strongest in women for localized cancer, while stronger in men for more advanced stages.
A study by Kumamoto University researchers found that the molecule Folliculin (FLCN) acts as a gatekeeper to maintain separation between blood and lymphatic vessels. The discovery sheds light on how these two vessel types form independent networks, with potential implications for cancer metastasis and treatment of lymphedema.
A randomized clinical trial found that endocrine therapies can reduce estradiol levels in men with hormone receptor-positive breast cancer after three months of treatment. The study suggests a potential new approach for male breast cancer patients.
The CIC biomaGUNE BioNanoPlasmonics research team has grown three-dimensional tumours in scaffolds containing plasmonic nanoparticles to study cancer growth and dynamics. They aim to gain insight into tumour evolution over time by monitoring metabolites, temperature, and pH.
A collaborative research group identified an inhibitor of the glutamate metabolic enzyme GLS1 that selectively eliminates senescent cells in vivo. Administration of GLS1 inhibitors to aged mice removed senescent cells from various organs, ameliorating tissue dysfunction and age-related diseases such as obese diabetes and arteriosclerosis.
Researchers discovered that three patients with DOCK8 deficiency spontaneously repaired their faulty genes through somatic reversion, restoring normal immune function. This breakthrough has implications for future therapies and treatments for the often-fatal disease.
The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.
A recent study has found that women are less likely to receive guideline-recommended approaches for coronary artery bypass grafting (CABG), resulting in worse outcomes. This disparity may be attributed to delayed diagnosis of heart disease, which leads to undertreatment and poorer surgical results.
Research found that black patients diagnosed with non-small cell lung cancer are more likely to be diagnosed at an advanced stage and have lower chances of receiving surgery. Additionally, they experience significantly reduced cancer-specific survival rates compared to their white counterparts.
Researchers used XSEDE Stampede2 supercomputer to simulate polarized elongation of actin filaments, shedding light on their polymerization kinetics. The study's findings have potential applications in cancer treatment and development of self-healing materials.
Researchers at Children's Hospital Los Angeles have developed a new CAR T therapy that targets solid tumors in children, including neuroblastoma. The modified therapy uses a unique protein called synNotch to selectively kill cancer cells while sparing healthy tissue.
Scientists have discovered a previously unknown enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, which could lead to new approaches for treating EBV-associated cancers. The study sheds light on how this protein helps replicate and maintain the viral genome in infected cells.
Researchers will collaborate on new approaches to treating head and neck cancers associated with Fanconi anemia and human papillomavirus (HPV). The funding will support research into genetic defects that cause these cancers, which have higher rates in Black people, particularly men.
The Minnesota Partnership has awarded five teams with nearly $5 million in research grants to develop a long-lasting COVID-19 vaccine, new treatments for breast and other cancers, and gene-editing techniques to prevent birth defects. The projects will focus on improving treatment of diseases such as cancer and genetic disorders.
Scientists at Thomas Jefferson University discovered that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair mechanisms. The study found that CRY-1 is strongly associated with poor outcomes in late-stage prostate cancers.
A study of 419 breast MRI examinations found new suspicious findings in 5.5% of patients, but all were benign; results suggest biopsies may not be necessary for patients responding well to neoadjuvant therapy.
This issue of APSB features studies on the anticancer effects of berberine, baicalein's potent antivirus ability against HSV-1, and a new class of PDE10A inhibitors for treating PAH. Additionally, several articles explore innovative drug delivery systems and novel targets for cancer therapy.
A recent study published in Cancer reveals that having multiple oral sex partners and engaging in high-intensity sex at a younger age significantly increase the likelihood of developing HPV-related oropharyngeal cancer. The research also found that older sexual partners and extramarital relationships are associated with higher risk.
Researchers improved understanding of intestinal stem cells' renewal and differentiation into specialized cell types. They identified a specific Wnt/planar cell polarity pathway regulating intestinal stem cell self-renewal and lineage decisions, crucial for treating diseases like diabetes and colorectal cancer.
Researchers developed a novel, patient-derived model of ulcerative colitis to identify promising targets for new treatments. The model showed that inhibiting CXCL8 expression slowed disease progression.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
Scientists at The Wistar Institute have developed an ACSS2 inhibitor that impairs cancer growth in preclinical models by depriving malignant cells of a critical nutrient source. This approach targets acetate metabolism, which is essential for tumor growth under conditions of low nutrient and oxygen availability.
Researchers at Osaka University discovered that liver cancer cells induce autophagy in nearby stromal cells, leading to the secretion of GDF15, which enhances tumor growth. High levels of GDF15 are associated with a poorer prognosis in HCC patients.